SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Thursday, November 13, 2025, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Thursday, November 13th, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:https://edge.media-server.com/mmc/p/4jh5a49o Participants may a ...

SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) participated in The American Society of Human Genetics (ASHG) conference from October 14–18, 2025 in Boston. The event highlighted the potential for an expanding role of optical genome mapping (OGM) in genetic disease research. Multiple presentations and posters showcased its effectiveness in detecting structural variants (SVs) associated with a range of genetic conditions, including facioscapulohumeral muscular dystrophy (FS ...

Summary of Bionano Genomics Conference Call (October 15, 2025) Company Overview - **Company**: Bionano Genomics (NasdaqCM: BNGO) - **Industry**: Optical Genome Mapping (OGM) technology Key Points and Arguments OGM Technology - **Definition**: OGM is a workflow that allows clinical researchers to analyze DNA for diseases such as hematologic malignancies and genetic disorders, as well as in pharmaceutical drug development [2][3] - **Differentiation**: OGM analyzes ultra high molecular weight DNA segments (hundreds of thousands of base pairs) compared to traditional sequencing methods that analyze shorter segments (hundreds of base pairs) [4][8] - **Applications**: OGM is used for detecting large structural variations in DNA, which are critical in cancer research and genetic disease analysis [10][21] Market and Customer Base - **Target Customers**: Primarily cytogenetic laboratories within pathology departments, as well as molecular pathology departments [15][16] - **Existing Customers**: Includes major cancer centers like MD Anderson and Memorial Sloan Kettering, with an estimated 2,500 labs in the U.S. and Western Europe processing around 1 million samples annually [19][20] - **Market Potential**: The total addressable market includes an additional 7,500 laboratories globally that could adopt OGM in the future [52] Instruments and Software - **Instruments**: Two main systems, Saphyr and Stratus, with Stratus designed for higher throughput (up to 10,000 samples per year) compared to Saphyr (2,500 samples per year) [28][30] - **Software**: The Via software is used for analyzing and reporting variants from OGM and other genomic data, with a significant revenue stream from software sales [35][38] Financial Performance - **Revenue Breakdown**: Instruments and consumables generated approximately $5.5 million, while services and software contributed around $1.6 million [80] - **Revenue Guidance**: Expected revenue for 2025 is between $26 million and $30 million, with a focus on increasing utilization among existing customers [86][88] Competitive Landscape - **Market Position**: Bionano is the only company providing OGM technology, with a strong intellectual property portfolio protecting against competitors [78][79] - **Software Competition**: While there are other software platforms, Via is recognized as a leading tool for analyzing structural variations [41] Challenges and Barriers - **Adoption Barriers**: Initial skepticism regarding OGM's effectiveness has been addressed through numerous publications demonstrating its utility [66][67] - **CPT Codes**: The establishment of CPT codes for hematologic malignancies and constitutional genetic disorders has removed a significant barrier to adoption [69][70] Future Outlook - **Growth Strategy**: Focus on increasing utilization in existing labs rather than aggressive new customer acquisition, aiming for double-digit growth in consumables [86][88] - **Regulatory Environment**: Positive developments regarding FDA regulations and the absence of significant regulatory hurdles for laboratory-developed tests [76][77] Stock Performance - **Recent Challenges**: The company faced stock price contraction due to industry-wide issues and a reverse stock split, but recent financing has provided a runway for future growth [90][91] Additional Important Information - **Automation Solutions**: Bionano is working on automating the DNA isolation step to increase throughput in labs [72][73] - **Guidelines and Recommendations**: Efforts are underway to have OGM included in clinical guidelines, which would further drive adoption [74]

Core Insights - Bionano Genomics, Inc. will have its CEO, Erik Holmlin, participate in the H.C. Wainwright @ Home Event on October 15, 2025 [1][2] Company Overview - Bionano Genomics provides genome analysis solutions aimed at helping researchers and clinicians address complex biological and medical questions [3] - The company's mission is to revolutionize genome visualization through optical genome mapping (OGM) solutions, diagnostic services, and software [3] - Bionano offers OGM solutions applicable in basic, translational, and clinical research, along with a leading platform-agnostic genome analysis software and nucleic acid extraction solutions using proprietary isotachophoresis (ITP) technology [3] - Through its subsidiary, Lineagen, Inc. d/b/a Bionano Laboratories, the company provides OGM-based diagnostic testing services [3]

Group 1 - Bionano Genomics, Inc. has launched a public offering of 5 million shares at a price of $2.00 per share, aiming to generate $10 million in gross proceeds, with potential additional funds of $20 million if warrants are fully exercised [1][2] - The funds from the offering are intended to support general corporate needs and will provide a solid foundation for the company's expansion into clinical and anatomic pathology [2][3] - The company is focusing on enhancing utilization among routine users, strengthening its installed base, accelerating adoption of its VIA software, and developing reimbursement support for its optical genome mapping (OGM) technology [3][4] Group 2 - Bionano Genomics, Inc. is based in San Diego, California, and specializes in genome analysis solutions, aiming to transform the understanding of the genome since its founding in 2003 [4]

Market Overview - U.S. stocks traded mostly higher, with the Nasdaq Composite gaining over 100 points on Thursday [1] - The Dow decreased by 0.04% to 46,000.59, while the NASDAQ rose by 0.49% to 22,370.12 and the S&P 500 increased by 0.29% to 6,619.34 [1] Sector Performance - Information technology shares increased by 0.8% on Thursday [1] - Materials stocks fell by 0.7% [2] Economic Indicators - U.S. initial jobless claims declined by 33,000 to 231,000 in the second week of September, better than market estimates of 240,000 [3][9] - The Philadelphia Fed Manufacturing Index rose to +23.2 in September, the highest level since January, compared to -0.3 in August [11] Commodity Prices - Oil prices increased by 0.5% to $64.37, while gold decreased by 0.4% to $3,701.70 [6] - Silver fell by 0.1% to $42.110 and copper dropped by 0.5% to $4.6135 [6] International Markets - European shares were higher, with the eurozone's STOXX 600 rising by 0.8% [7] - Asian markets closed mixed, with Japan's Nikkei gaining 1.15% and Hong Kong's Hang Seng falling by 1.35% [8] Company News - 89bio, Inc. shares surged 85% to $14.97 after announcing an acquisition agreement with Roche [10] - Aeries Technology, Inc. shares also rose 85% to $1.0500 following a partnership announcement with an annual contract value of up to $8 million [10] - Aptevo Therapeutics Inc. shares increased by 57% to $2.2201 after breakthrough clinical results [10] - Replimune Group, Inc. shares dropped by 40% to $3.4288 as the company evaluates FDA feedback [10] - BioCardia, Inc. shares fell by 34% to $1.02 after announcing a public offering and trial results [10] - Office Properties Income Trust shares decreased by 28% to $0.4066 [10]

Core Viewpoint - Bionano Genomics, Inc. has successfully closed a public offering, raising approximately $10 million, with potential additional proceeds of around $20 million from Series Warrants if fully exercised [1][3]. Group 1: Offering Details - The public offering consisted of 5,000,000 shares of common stock and Series E and Series F warrants, all priced at $2.00 per share [1]. - The Series E warrants will expire five years after issuance, while the Series F warrants will expire eighteen months after issuance [1]. - H.C. Wainwright & Co. served as the exclusive placement agent for the offering [2]. Group 2: Financial Implications - The gross proceeds from the offering were approximately $10 million before deducting fees and expenses [3]. - If the Series Warrants are fully exercised, the potential additional gross proceeds could reach approximately $20 million [3]. - The net proceeds from the offering are intended for working capital and general corporate purposes [3]. Group 3: Company Overview - Bionano Genomics provides genome analysis solutions aimed at enhancing research and clinical applications [6]. - The company focuses on optical genome mapping (OGM) solutions and offers diagnostic services and software [6]. - Bionano's mission is to transform genome analysis through innovative technologies, including proprietary isotachophoresis (ITP) [6].

Market Overview - The market has experienced significant shifts, with several companies facing notable price declines due to sector-specific challenges and broader economic conditions [1] REX American Resources Corporation - REX American Resources Corporation's stock price has dropped over 50% to $30.54, facing potential operational challenges and broader market conditions affecting the Basic Materials sector [2] - The company's recent announcement regarding the conversion of REX-Osprey™ SOL + Staking ETF to a Regulated Investment Company structure may be a strategic move to enhance investor returns, but it may not have an immediate impact on REX's stock performance [2] Charles & Colvard, Ltd. - Charles & Colvard, Ltd. has seen a 42.65% decrease in its stock price to $0.43, facing challenges in the Luxury Goods and Consumer Cyclical sector [3] - The company's delisting from Nasdaq marks a significant change in its trading status, potentially contributing to the stock's decline [3] Bionano Genomics, Inc. - Bionano Genomics, Inc. experienced a 38.81% decline in its stock price to $1.69, specializing in genome analysis solutions [4] - Despite showcasing the utility of optical genome mapping in cancer biomarker analysis, market sentiment towards biotech investments and specific operational news may have contributed to the price drop [4] Osisko Development Corp. Warrant - Osisko Development Corp. Warrant saw a 32.43% decline to $0.25, with price movements influenced by fluctuations in gold prices and investor sentiment towards the Basic Materials sector [5] BT Brands, Inc. - BT Brands, Inc. experienced a 31.36% decline in its stock price to $0.31, operating in the quick-service restaurant industry [6] - The company faces challenges in the Consumer Cyclical sector, with market competition and broader economic factors affecting consumer spending potentially contributing to the stock's decline [6] Conclusion - The movements in these companies underscore the volatility and diverse factors influencing the market, with investors and analysts likely to monitor these developments for insights into the underlying causes of price changes and their potential long-term implications [7]

U.S. Stock Market - U.S. stocks traded mostly lower, with the Dow Jones index falling more than 150 points, down 0.37% to 45,713.02 [1] - NASDAQ fell 0.03% to 22,341.05, and S&P 500 dropped 0.14% to 6,605.77 [1] - Energy shares increased by 1.1%, while utilities stocks fell by 0.8% [1] Company Performance - Dave & Buster's Entertainment Inc. reported second-quarter revenue of $557.41 million, missing analyst estimates of $562.78 million [2] - Adjusted earnings for Dave & Buster's were 40 cents per share, below estimates of 92 cents per share [2] Commodities - Oil prices increased by 2.2% to $64.70, while gold rose by 0.2% to $3,726.00 [5] - Silver traded up 0.1% to $43.000, and copper fell 0.1% to $4.7120 [5] European Markets - European shares were lower, with the eurozone's STOXX 600 falling 0.86% [6] - Spain's IBEX 35 Index decreased by 1.30%, and London's FTSE 100 fell 0.74% [6] Asian Markets - Asian markets closed mostly higher, with Japan's Nikkei gaining 0.30% and India's BSE Sensex increasing by 0.73% [7] Notable Stock Movements - Turbo Energy, S.A. shares surged 408% to $13.72 after securing a $53 million contract for energy storage projects in Spain [8] - WEBTOON Entertainment Inc. shares rose 28% to $19.13 following a non-binding agreement with Disney [8] - Jumia Technologies AG shares increased by 22% to $11.90 after an upgrade from RBC Capital [8] - Bionano Genomics, Inc. shares dropped 41% to $1.6398 due to a $10 million public offering announcement [8] - GD Culture Group Limited shares fell 19% to $7.84 after entering a share exchange agreement [8] - Next Technology Holding Inc. shares decreased by 17% to $23.79 after filing for a stock shelf of up to $500 million [8] Economic Indicators - U.S. business inventories increased by 0.2% month-over-month in July, aligning with market estimates [11] - The NAHB/Wells Fargo Housing Market Index remained steady at 32 in September [11] - U.S. industrial production rose by 0.1% in August, exceeding market expectations [11] - U.S. retail sales increased by 0.6% month-over-month in August, surpassing expectations [11] - Export and import prices both rose by 0.3% in August [11]

U.S. Stock Market - U.S. stocks traded mostly lower, with the Dow Jones index falling more than 150 points, down 0.37% to 45,713.02 [1] - The NASDAQ fell 0.03% to 22,341.05, and the S&P 500 dropped 0.14% to 6,605.77 [1] - Energy shares increased by 1.1%, while utilities stocks fell by 0.8% [1] Company Performance - Dave & Buster's Entertainment Inc. reported second-quarter revenue of $557.41 million, missing analyst estimates of $562.78 million [2] - The company reported adjusted earnings of 40 cents per share, falling short of estimates of 92 cents per share [2] Commodity Market - Oil prices increased by 2.2% to $64.70, while gold rose by 0.2% to $3,726.00 [5] - Silver traded up 0.1% to $43.000, and copper fell by 0.1% to $4.7120 [5] European Market - European shares were lower, with the eurozone's STOXX 600 falling 0.86% [6] - Spain's IBEX 35 Index decreased by 1.30%, London's FTSE 100 fell 0.74%, Germany's DAX 40 dipped 1.29%, and France's CAC 40 fell 0.72% [6] Asian Market - Asian markets closed mostly higher, with Japan's Nikkei gaining 0.30% and India's BSE Sensex increasing by 0.73% [7] Notable Stock Movements - Turbo Energy, S.A. shares surged 408% to $13.72 after securing a $53 million contract for energy storage projects in Spain [8] - WEBTOON Entertainment Inc. shares rose 28% to $19.13 following a non-binding agreement with Disney [8] - Jumia Technologies AG shares increased by 22% to $11.90 after an upgrade from RBC Capital [8] - Bionano Genomics, Inc. shares dropped 41% to $1.6398 due to a $10 million public offering announcement [8] - GD Culture Group Limited shares fell 19% to $7.84 after entering a share exchange agreement [8] - Next Technology Holding Inc. shares decreased by 17% to $23.79 after filing for a stock shelf of up to $500 million [8] Economic Indicators - U.S. business inventories increased by 0.2% month-over-month in July, aligning with market estimates [11] - The NAHB/Wells Fargo Housing Market Index remained steady at 32 in September [11] - U.S. industrial production rose by 0.1% in August, exceeding market expectations [11] - U.S. retail sales increased by 0.6% month-over-month in August, surpassing expectations [11] - Export and import prices both rose by 0.3% in August [11]